Cargando…

Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective

Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic si...

Descripción completa

Detalles Bibliográficos
Autores principales: Trandafir, Laura M., Dodi, Gianina, Frasinariu, Otilia, Luca, Alina C., Butnariu, Lacramioara I., Tarca, Elena, Moisa, Stefana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/
https://www.ncbi.nlm.nih.gov/pubmed/36145147
http://dx.doi.org/10.3390/nu14183774
_version_ 1784796130770419712
author Trandafir, Laura M.
Dodi, Gianina
Frasinariu, Otilia
Luca, Alina C.
Butnariu, Lacramioara I.
Tarca, Elena
Moisa, Stefana M.
author_facet Trandafir, Laura M.
Dodi, Gianina
Frasinariu, Otilia
Luca, Alina C.
Butnariu, Lacramioara I.
Tarca, Elena
Moisa, Stefana M.
author_sort Trandafir, Laura M.
collection PubMed
description Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic side effects. Therefore, novel solutions for tackling obesity-associated diseases and providing insights into the development of innovative or improved therapies are necessary. Targeted nanotherapy is a revolutionary technology, offering a promising solution for combatting the disadvantages of currently available therapies for treating obesity and dyslipidemia due to its superior features, which include specific cell targeting, the protection of drugs against physiological degradation, and sustained drug release. This review presents a brief assessment of obesity and dyslipidemia, their impacts on human health, current treatment, and limitations, and the role and potential use of nanotechnology coupled with targeted drug delivery and nutraceuticals as emerging therapies. To the best of our knowledge, this paper presents, for the first time in the literature, a comparison between obesity and dyslipidemia nano-formulations based on drugs and/or natural extracts applied in experimental studies.
format Online
Article
Text
id pubmed-9504099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95040992022-09-24 Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective Trandafir, Laura M. Dodi, Gianina Frasinariu, Otilia Luca, Alina C. Butnariu, Lacramioara I. Tarca, Elena Moisa, Stefana M. Nutrients Review Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic side effects. Therefore, novel solutions for tackling obesity-associated diseases and providing insights into the development of innovative or improved therapies are necessary. Targeted nanotherapy is a revolutionary technology, offering a promising solution for combatting the disadvantages of currently available therapies for treating obesity and dyslipidemia due to its superior features, which include specific cell targeting, the protection of drugs against physiological degradation, and sustained drug release. This review presents a brief assessment of obesity and dyslipidemia, their impacts on human health, current treatment, and limitations, and the role and potential use of nanotechnology coupled with targeted drug delivery and nutraceuticals as emerging therapies. To the best of our knowledge, this paper presents, for the first time in the literature, a comparison between obesity and dyslipidemia nano-formulations based on drugs and/or natural extracts applied in experimental studies. MDPI 2022-09-13 /pmc/articles/PMC9504099/ /pubmed/36145147 http://dx.doi.org/10.3390/nu14183774 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Trandafir, Laura M.
Dodi, Gianina
Frasinariu, Otilia
Luca, Alina C.
Butnariu, Lacramioara I.
Tarca, Elena
Moisa, Stefana M.
Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title_full Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title_fullStr Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title_full_unstemmed Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title_short Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
title_sort tackling dyslipidemia in obesity from a nanotechnology perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/
https://www.ncbi.nlm.nih.gov/pubmed/36145147
http://dx.doi.org/10.3390/nu14183774
work_keys_str_mv AT trandafirlauram tacklingdyslipidemiainobesityfromananotechnologyperspective
AT dodigianina tacklingdyslipidemiainobesityfromananotechnologyperspective
AT frasinariuotilia tacklingdyslipidemiainobesityfromananotechnologyperspective
AT lucaalinac tacklingdyslipidemiainobesityfromananotechnologyperspective
AT butnariulacramioarai tacklingdyslipidemiainobesityfromananotechnologyperspective
AT tarcaelena tacklingdyslipidemiainobesityfromananotechnologyperspective
AT moisastefanam tacklingdyslipidemiainobesityfromananotechnologyperspective